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Monday, February 22, 2010 353aphosphorylation. Molecular modeling of cTnT-DK210 structure reveals
changes in the electrostatic environment of cTnT helix (residues 203-224)
that lead to a more basic environment around Thr203, which enhances PKC-de-
pendent phosphorylation. In addition, yeast two-hybrid assays indicate that
cTnT-DK210 has enhanced binding to cTnI compared with cTnT-wt, and
may impair Ca2þ sensing/transmission leading to myofilament desensitization.
Collectively, our observations suggest that cardiomyopathy-causing DK210
has far-reaching effects influencing posttranslational modifications of key sar-
comeric proteins, and potentially cTnI-cTnT interaction.
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Crystal structures of the troponin ‘‘core-domain’’ formed in the presence and
absence of Ca2þ display a bilobed TnC subunit mounted on a semi-rigid scaf-
fold formed from major stretches of TnI and TnT. A central coiled-coil of TnI
and TnT is flanked by single TnI and TnT helices to form the W-shaped sup-
porting structure, which appears to be little changed by the binding of Ca2þ
(Takeda et al., 2003; Vinogradova et al., 2005). In contrast, at low Ca2þ, the
central helix joining C- and N-lobes of TnC melts, and the ‘‘regulatory’’ C-ter-
minal domain of TnI dissociates from the N-lobe of TnC (Vinogradova et al.,
2005). Consistent with biochemical studies, the C-terminal TnI sequences in
the thin filament are thought to latch onto actin and constrain tropomyosin in
the blocked state at low-Ca2þ. Their dissociation from actin at high-Ca2þ
and association with the N-terminal lobe of Ca2þ-saturated TnC may relieve
the constraint (Galinksa-Rakoczy et al., 2008). These conclusions remain un-
certain, however, because troponin is only semi-rigid (so crystal packing forces
may have influenced the structure) and the troponin complex used for crystal-
lization contained truncated subunits. Here we have studied isolated, intact tro-
ponin molecules using negative stain electron microscopy and single-particle
image processing. Averaged projection views and 3D reconstructions of the
isolated molecules show many of the same features seen in the crystal struc-
tures. Comparison of reconstructions of low and high Ca2þ data suggests that
the TnC N-lobe of cardiac troponin may be further from the core domain in
the EM than in the crystal structure.
Funding: HSJ (KBSI-T29760); NIH: WL (HL36153), LST (HL38834,
HL63774), RC (AR34711, RR08426).
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The cardiac myofilament is a protein assembly that provides Ca-regulated force
development enabling the heart to undergo alternating periods of contraction
and relaxation. Troponin (Tn), a three-member protein assembly within the
myofilament, acts as a Ca-sensitive switch. Here, using single pair FRET in
freely diffusing assemblies of Tn, we show that Tn incompletely activates after
binding regulatory Ca. The reserved population of inactive Tn appears to func-
tion as a nanoscopic form of cardiac reserve that can be can be manipulated by
cell signaling mechanisms to fine-tune cardiac contractility. The results are dis-
cussed in terms of an energetic model of the cardiac myofilament.
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In vitro investigation of the effects of cardiomyopathy-causing mutations in
thin filament regulatory proteins has demonstrated that hypertrophic cardiomy-
opathy (HCM) and dilated cardiomyopathy (DCM) are caused by distinct pri-
mary alterations of cardiac contractility and myofilament calcium affinity. We
hypothesise that chronically altered calcium-buffering by mutant thin filaments
leads to altered calcium handling and, via calcium-dependent signalling path-ways, contributes to disease pathogenesis. We aim to study the in situ effect
on calcium flux of a HCM and a DCM causing mutation in human cardiac tro-
ponin T (cTnT) (R92Q, R131W respectively), by adenoviral mediated expres-
sion of mutant protein in adult guinea pig cardiomyocytes. The adenoviral vec-
tors co-express GFP and western blot analysis of FACS-sorted, GFP-expressing
cells showed that recombinant cTnT comprised 45-50% of the total cTnT in
these cardiomyocytes, 48 hours after infection. Analysis of unloaded sarcomere
shortening showed that at an excitation frequency of 2 Hertz, cardiomyocytes
infected with R131W cTnT elongated the time to 50% relaxation and reduced
the magnitude of contraction, whilst R92Q cTnT reduced the time to 50% re-
laxation and increased the contractile magnitude compared to wild type. Anal-
ysis of calcium transients of the same cells using fura-2 loading, indicates that
the R92Qmutation reduces calcium transient amplitude, whilst the R131Wmu-
tation increases the time to complete calcium reuptake, with no change to the
transient amplitude, despite the observed decrease in contraction. We are
currently assessing the caffeine transients of these cells to investigate alter-
ations to overall SR load and measuring alterations to components of cal-
cium-dependent signalling cascades which may link the acute effects of
cTnT mutations to macroscopic remodelling observed in the pathological dis-
ease states of HCM and DCM.
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Smooth muscle contraction is driven by cyclical, nucleotide-dependent changes
in myosin conformation that alter its affinity for actin, produce force, and gen-
erate movement. We used a high throughput screen to identify compounds that
inhibit the ATPase activity of smooth muscle myosin; optimization of the ini-
tial hit compounds has resulted in compounds with nanomolar affinity. A potent
representative of this chemical series, CK-2018571, inhibits the steady-state
ATPase activity of human smooth muscle myosin at low nanomolar concentra-
tions, approximately 10-fold lower than are required to inhibit non-muscle my-
osin, the most closely related myosin II. Selectivity between smooth and stri-
ated myosin IIs are >100-fold. Transient kinetic studies demonstrate that
CK-2018571 inhibits the myosin-catalyzed hydrolysis of the g-phosphate
group of ATP, with no effect on nucleotide binding or release from the enzyme.
Actin co-sedimentation assays indicate that CK-2018571 stabilizes a weak ac-
tin-binding conformation of myosin in the presence of ATP. Consistent with
this mechanism, CK-2018571 relaxes skinned rat tail artery muscle tissue at
low micromolar concentrations. Importantly, this relaxation occurs regardless
of whether the skinned muscle has been activated by calcium or by thiophos-
phorylation of the myosin regulatory light chain, supporting evidence that
CK-2018571 relaxes smooth muscle tissue by direct inhibition of activated
smooth muscle myosin. The ability of CK-2018571 to relax intact tracheal
smooth muscle and aortic ring preparations at micromolar concentrations sug-
gests this mechanism may prove useful in diseases of smooth muscle hyper-
contractility, such as hypertension and asthma.
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Both the Ca2þ signal and the alteration of the Ca2þ sensitivity of the contractile
apparatus regulate smooth muscle contraction. Myosin light chain kinase
(MLCK) phosphorylated the 20 kDa regulatory myosin light chain (MLC20)
resulting in contraction. Myosin light chain phosphatase (MLCP) dephosphor-
ylates MLC20 causing relaxation. Thus, the balance between the activities of
MLCK and MLCP determines the level of MLC20 phosphorylation.
MLCP consists of a 38 kDa catalytic subunit (PP1cd), a 110 kDa targeting sub-
unit (MYPT1), and a 21 kDa small subunit (M21). MYPT1 provides the sub-
strate specificity and the regulation of phosphatase activity. It was reported
that myosin phosphatase-Rho interacting protein (M-RIP) bound MYPT1 and
thus targeted MLCP to the actomyosin contractile filament based on yeast-
two hybrid and cell biological assays.
To determine if MYPT1 binds to M-RIP directly, we performed analytical ul-
tracentrifugation (AUC) study using purified peptides of MYPT1 and M-RIP.
